Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
- PMID: 31416769
- DOI: 10.1016/S2213-2600(19)30250-4
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
Abstract
Background: Idiopathic interstitial pneumonias are often complicated by pulmonary hypertension, increasing morbidity and mortality. There are no approved treatments for pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP). We aimed to evaluate the efficacy and safety of riociguat in patients with PH-IIP.
Methods: RISE-IIP was a double-blind, randomised, placebo-controlled study done at 65 pulmonary hypertension and interstitial lung disease centres in 19 countries to evaluate the efficacy and safety of riociguat in patients with PH-IIP. Eligible patients were adults (aged 18-80 years) diagnosed with idiopathic interstitial pneumonia (as per American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines), forced vital capacity (FVC) of at least 45%, 6MWD of 150-450 m, WHO functional classes II-IV, precapillary pulmonary hypertension confirmed by right heart catheterisation, systolic blood pressure of at least 95 mm Hg, and no signs or symptoms of hypotension. Patients were randomly allocated (1:1) using an interactive voice and web response system to riociguat (0·5-2·5 mg three times daily) or placebo for 26 weeks (main study), after which they could enter an open-label extension in which all patients received riociguat. The primary endpoint was change in 6-min walking distance (6MWD) in the intention-to-treat population. Prespecified safety variables included adverse events and serious adverse events, laboratory parameters, and adverse events of special interest (haemoptysis and symptomatic hypotension), assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02138825.
Findings: Between June 4, 2014, and May 5, 2016, we enrolled 229 participants. After the exclusion of 82 participants, 147 were randomly allocated to treatment (73 to riociguat, 74 to placebo). The study was terminated early (median treatment duration 157 days [range 6-203]) at the request of the data monitoring committee owing to increased serious adverse events (main study: 27 [37%] of 73 participants in the riociguat group vs 17 [23%] of 74 in the placebo group) and mortality in patients receiving riociguat, and the absence of efficacy signals in the riociguat group. 11 patients died in the main study (eight in the riociguat group, three in the placebo group), and nine died in the extension phase (one in the riociguat group, eight in the former placebo group; all received riociguat). In the main study, the most common adverse events were peripheral oedema (16 [22%] of 73 in the riociguat group vs seven [9%] of 74 in the placebo group) and diarrhoea (11 [15%] vs seven [9%]). The most common serious adverse events were worsening of interstitial lung disease (main study: six [8%] of 73 in the riociguat group vs five [7%] of 74 in the placebo group) and pneumonia (four [5%] vs one [1%]). Riociguat did not improve 6MWD versus placebo at 26 weeks (least-squares mean difference 21 m; 95% CI -9 to 52).
Interpretation: In patients with PH-IIP, riociguat was associated with increased serious adverse events and mortality, and an unfavourable risk-benefit profile. Riociguat should not be used in patients with PH-IIP.
Funding: Bayer AG and Merck & Co.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
Pulmonary hypertension associated with idiopathic interstitial pneumonia: is effective pharmacotherapy an impossible dream?Lancet Respir Med. 2019 Sep;7(9):727-728. doi: 10.1016/S2213-2600(19)30266-8. Epub 2019 Aug 12. Lancet Respir Med. 2019. PMID: 31416766 No abstract available.
-
RISE-IIP: some pitfalls and observations.Lancet Respir Med. 2019 Nov;7(11):e35. doi: 10.1016/S2213-2600(19)30378-9. Lancet Respir Med. 2019. PMID: 31645285 No abstract available.
Similar articles
-
Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.Chest. 2022 Feb;161(2):448-457. doi: 10.1016/j.chest.2021.07.2162. Epub 2021 Aug 4. Chest. 2022. PMID: 34363816 Free PMC article. Clinical Trial.
-
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
-
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study.J Heart Lung Transplant. 2021 Jun;40(6):494-503. doi: 10.1016/j.healun.2021.02.006. Epub 2021 Feb 19. J Heart Lung Transplant. 2021. PMID: 33744088 Clinical Trial.
-
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Respir Med. 2017 Aug;129:124-129. doi: 10.1016/j.rmed.2017.05.005. Epub 2017 May 15. Respir Med. 2017. PMID: 28732819 Review.
-
Riociguat: a novel new drug for treatment of pulmonary hypertension.Pharmacotherapy. 2015 May;35(5):502-19. doi: 10.1002/phar.1592. Pharmacotherapy. 2015. PMID: 26011143 Review.
Cited by
-
Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.Int J Chron Obstruct Pulmon Dis. 2024 May 23;19:1105-1121. doi: 10.2147/COPD.S454905. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 38803412 Free PMC article. Clinical Trial.
-
Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response.ERJ Open Res. 2024 May 20;10(3):00959-2023. doi: 10.1183/23120541.00959-2023. eCollection 2024 May. ERJ Open Res. 2024. PMID: 38770008 Free PMC article.
-
Pulmonary Arterial Hypertension Therapy in Pulmonary Hypertension Associated With Lung Diseases.JACC Asia. 2024 Apr 23;4(5):418-420. doi: 10.1016/j.jacasi.2024.03.001. eCollection 2024 May. JACC Asia. 2024. PMID: 38765658 Free PMC article.
-
The acute effect of inhaled nitric oxide on the exercise capacity of patients with advanced interstitial lung disease: a randomized controlled trial.BMC Pulm Med. 2024 May 10;24(1):226. doi: 10.1186/s12890-024-03051-4. BMC Pulm Med. 2024. PMID: 38724947 Free PMC article. Clinical Trial.
-
Pulmonary Vasodilator Therapy Is Associated with Decreased Mortality in Patients with Chronic Lung Disease and Severe Pulmonary Hypertension.J Cardiovasc Dev Dis. 2024 Mar 8;11(3):89. doi: 10.3390/jcdd11030089. J Cardiovasc Dev Dis. 2024. PMID: 38535112 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical